michelcarroll/llama2-earnings-stock-prediction-fine-tune huggingface dataset:
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Rich, this is Steve Lindsey. I'll start. Yes. Basically, the process right now is, it was brought forward by the environmental defense fund, and it's really addressing the FERC process. It's not the STL Pipeline per se, but it was their process in improving that. So, that pipeline has been operating since November of 2019. So, we're -- well over a year. It's been operating very efficiently. We're accessing supply from parts of the country for our customers here that we didn't have before. And the one thing that I will say is with some of the interconnects that we've recently made and some of the other operational benefits that are coming, the benefits from the pipeline are even better and larger than we thought originally. And so, that even to me, makes the case even stronger. From a timing perspective right now, I believe oral arguments are due to be in March relative to the case right now. And then we'll just have to go from there. But we feel very confident in the rationale behind the original certificate that was received. In the event that we have to go through that process again, we think if anything, additional benefits have been added to the original case.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes, sure. So we have picked up share in the United States as well as in Europe recently and I think that cusp overlap lowering the pacemaker rate and increasing the predictability of the procedure has been really helpful. In Europe, we launched the PRO+ just recently. We've got also approval, as you know, in Japan for the low risk indication. Typically, it's about a quarter before that reimbursement gets in line with that and then, of course, China is an opportunity for us, we've been working on a local clinical strategy there and we have good progress going. There's a lot of [Technical Issue] our solution.
China is a little bit of a nascent market yet for TAVR. It's still on a good growth curve, but it's restricted to just a few centers within the very big cities at this point in time. I think really the penetration into low risk everywhere typically the United States and Europe continues to be the biggest growth driver and of course, as we expand into asymptomatic patients in the future [Indecipherable].
Everything is looking pretty good in TAVR but for the COVID challenges that happened because of the concentrated nature of that business [Indecipherable]. Feel really good about where we are with pipeline. FX is going to be a really big improvement and the predictability of [Technical Issues] has been really a home run for us.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. No, we're not seeing any impact on implant choice. If they're moving to the hospital outpatient or even, frankly, to the surgery center, thus far, we're seeing surgeons continue to operate with the same implants -- so regardless of which facility they're operating in.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Sure, I -- we definitely see ourselves as being in a privileged and strong position from an M&A standpoint whether it be again our financial wherewithal, our bandwidth to do M&A, both financial and human, the balance sheet, and so we still remain very confident on that front. I don't know that I would say that the chip shortage and supply chain challenges are necessarily unlocking any opportunities that we would not have already had in our pipeline. We remain continued focused on what our priorities are strategically in that area. And that really is around we see some opportunities to these both ends with utilities, industrial, commercial building, continue to be areas that we are very positive and very focused on.
Again it takes two to tango. And so again, we'll keep you updated on that. We feel -- we're very confident. We're very excited about the M&A pipeline but I wouldn't say it's changed dramatically because of the supply chain situation.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, we, I think we said that there was, our staff is fundamentally, our staffing levels are fundamentally flat, and we're operating now with 700 less of ADC. So Chris has been focusing on finding out where we have capacity and then we've been doubling down on our BD efforts to make sure that we push those efforts to take extra capacity. So in these areas, we've been stealing share. So we're happy with that. We call it pitching and catching. Our BD folks pitch and our clinicians catch. So we feel that we're, our balance is very good. We're building up the BD side where we did have a deficit. And we're ahead on that. And the key thing is on our labor side. That's why we've been so focused. We knew the BD functions, we're going to be increasing tremendously. And therefore, we believe we have the labor in place. There are tight spots, for sure, since we're in 40 states, largely urban, but we've been working through those pretty well. On the TAM, I'm going to let Nick talk about that.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
We are at the end of time. If you do have follow-up questions, please do not hesitate to call, and thank everybody -- thank you everyone for your interest and time this morning.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
And when you say 70% to 80%, can you just clarify were you referring to exactly what, Brandt?

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
That's a great point, Ryan. Yes, so that's definitely the case. I think definitely, both sponsorship and accommodations have been impacted by the pandemic this year. And as we move into next year, we should start seeing recovery on that side as well. So -- but that's -- we agree with you.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yeah, absolutely. So, first on revenue, why we're not providing guidance is because there are a number of variables that are just really difficult to predict at this time with any level of credibility or confidence. The first being where is the trough in this most-recent surge that we're seeing, January, February, where does it land in Q1? What does that uptake look like post-adoption of the vaccine and then when do you ultimately return to normalized market growth and potential tailwind from the deferred procedures? So we're running a number of scenarios. There are some scenarios where you could see a path to growth versus 2019 but again, those variables are at this point just too uncertain.
But clearly, I think just stepping back, once we do have adoption, wide adoption of that vaccine, which we believe we'll have at some point in 2021, we think that there is a real opportunity for some strong growth again once the return to normalized market and are augmented by that tailwind but it's just too difficult to say what that cadence looks like at this time. Regarding margins, you're absolutely right as the margins -- as revenue continues to improve throughout the year, which we believe it will, once we have good uptake with the vaccine, but margins should follow. There may be a slight lag, consistent with how we've talked about things before, as we catch up on certain investments, but make no mistake, they will expand. And we do see the opportunity for significant margin expansion over time as we normalize our revenue uptake.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Okay, thank you all for joining the call.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
The amount wasn't very much, it's like $160,000. It's more of the change. We're still negative last quarters, so the delta was about $400,000, it was negative $200,000 some, followed by positive $160,000. So, overall, it was -- overall change was up $400,000.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, as we -- certainly, we do have the backlog. We -- as I mentioned, the challenges have been more on the issue of getting raw materials. We are -- 25% of our products are -- do come from outside our facilities, and that is where we have had even a greater issues because some of that 25% is offshore. Having said this, we have been -- we had a few hundred containers tied up, but they have now released. So those products will be coming in. Our manufacturing is starting to receive more, especially I'm talking about upholstery, where foam has been an issue. So I would say that we are going to have increases in production in this quarter.
And I think that how much more we will be able to do this quarter will really still depend upon receiving the products and time from overseas and the raw materials. But certainly, Brad, we're going to -- look, we should do better than what we did this quarter.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes, I will be at the quarter one results. So, you still have to bear with me one more quarter.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Well, it would over time, Mark. I mean, if inflation moves up materially from the kind of 4% to 5% inflation that we've talked about, then obviously, the cost models would pass that through on the reduced lags that we've been referring to. And so obviously, the things move along the way. And if we saw incremental inflation of substance continuing in the business, we would continue then to take other price actions across the other mechanisms that we have with market-based models as well. So this is a point in time based on all that we know specifically that we're trying to provide to you. And then obviously, it variates or is variable depending upon what we actually see relative to inflation over the coming quarters.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Sure. Steve and I will answer this one. Let me take the second one. So definitely, it was in our '25 numbers because it was assumed that they would convert and so that will share count. So what is different is that we have a higher share count '21 and '22 and '23. That is the only difference in these calculations. Regarding AES Next, the one that's producing the largest drag is Fluence. Quite frankly, Fluence as it matures and had -- it's made all these investments in new designs and gearing up to be able to meet that supply in terms of guaranteeing supply of batteries around the world. And if sales increase, your -- this will, I would say, gradually turn positive. So I think maybe, Steve, do you want to mention...

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
I think it's quite a unique circumstance in Australia, Tanya with the nature of sinking of mild deep shaft and relocation in a country that's got international borders closed. As we look into Ahafo North, which will be the next project where we're doing work a lot of the work in 2021 is ground clearing, road diversion and using local contractors with some of the plant coming through in 2022. And you'd expect to see some of the COVID restrictions lifting. So I'm not seeing the same level of cost escalation there as we're seeing in quite some unique circumstances for the scope of the work and the location for Tanami.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes, I mean, it's a great question. I'd say we'll probably -- they're obviously in the market on a stand-alone basis and even here in the U.S. So the first two things that we are on is one cross-selling that product back to our North American base and then I'd say 90 days we should be launched with our own channel, our own digital, our own field, and own people selling it to new prospects. So by the time we talk next time, we'll hopefully have some news for you.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. Thanks for taking my questions. A couple of follow-ups. And thanks for -- and also, thanks for providing visibility into '22 with minimum revenue of $1.5 billion. And the question I have here is, what are the key growth assumptions for different sectors? And if you don't want to elaborate, how should I think about the fastest growth versus the relatively lower growth segment?

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Sure. Hi. It's Jennifer. So we are really looking forward to our upcoming PDUFA date in the fourth quarter for our BCMA CAR-T.
This is going to be our first entry into cell therapy. And so the team -- the total team from R&D to supply chain to commercial has been really, really invested in this asset over the past couple of years, preparing to launch. I think the results that you've all seen and the really deep and durable responses that have been proven through our clinical programs really highlight that this is going to be a really meaningful and transformational asset for patients. As we had been planning the launch, we're really taking a thoughtful approach to scaling our global manufacturing, making sure that we're learning from those who've come before us.
And that we're really going to plan to deliver an optimal patient experience and a patient treatment or provider treatment center experience as well as we scale up. So the team has been working very heavily on this and we're gearing up for what we believe will be a very successful launch for patients, hopefully later this year. I also want to call out the very strong partnership that we have with Legend Biotech, where we've been attached at the hip throughout. And we're so excited to be working in partnership with them to be bringing that to market.
So looking forward to a good launch later this year.

    Prediction (one of UP, DOWN, SAME): UP
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
So, first of all, the litigation is quite extensive. And so, it's hard to get into any one particular case or situation and nor do we want to do that publicly, at least in an earnings conference call. And we -- the litigation, particularly intellectual property takes time, and we've been involved with this for quite some time. So, we're starting to see more action taking place within the court system. And everything that we've seen to date, we believe supports our position and we're confident that we're going to prevail in the medium to long term on these cases of infringement. We've had a couple of smaller cases settled in the recent quarter, which we are pleased to see and we would expect more of that to take place as we go forward. And we are making every possible effort to arrive at a mutually acceptable solution with those who infringe our technology. And we just feel that we innovated and have the intellectual property and expense in developing better solutions for the market and it's our responsibility to make sure that others don't infringe our innovations.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. So this is Bill. And I will refer everyone to the last slide in our corporate deck, which was refreshed and updated, is on our website, went up this morning. There we list out what we expect to deliver this year.
So we're talking about additional data from the 60-milligram multi-dose cohorts every four and every eight weeks in the first half, additional data from the 90-milligram multi-dose eight-week cohort in the first half, the 90-milligram 12-week data in the second half. We also expect to have some 90-milligram multi-dose eight-week dosing interval in HBV DNA positive subjects in the first half. I've already mentioned the two Phase 2 clinical studies we hope to kick off in the second half. And then as we already mentioned on this call, we expect to kick off the 836 Phase 1a/1b clinical study in the first half of the year.

    Prediction (one of UP, DOWN, SAME): SAME
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Now, it's a great wine, because it generates free cash flow, right. And so that's awesome and we love that. I mean, basically, when you think about dry powder we're going out to raise give or take $60 million from our clients for the value we deliver them and that puts dry powder on our balance sheet, which is a little different than other ways that people acquire dry powder.

    Prediction (one of UP, DOWN, SAME): DOWN
You are a financial analyst, determining what effect an earnings call will have on the company's stock price, based on a summary of one. Be as critical and skeptical as possible, and remember that the market may disproportionally react to small unexpected details. Respond with one of: UP, DOWN, SAME
 
Yes. What I would tell you is the great thing about salespeople is they're very creative, they're entrepreneurial and they want to follow where the market is to find the revenue. And so what I mean by that is, if customers are much more comfortable having in-person conversations and they want to move that way, then our sales force is certainly ready to do that. And there are absolutely cases where they're having on-site appointments today.
The salespeople also recognize that if they can do that virtually and avoid a drive and the customer is very comfortable, they'll do that. And so we want to make sure we arm our salespeople with all the tools they need to be successful, either virtually selling clients from their home office, as they're doing today, or getting back on site with customers and making sure that we can do it the way that the customers are most comfortable. I think like my answer before, you're going to see a bit of a hybrid and a bit of a new normal where it's going to happen both ways. And we're going to make sure that the sales reps are ready to do it either way.

    Prediction (one of UP, DOWN, SAME): SAME